Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress Supporting the Local Coverage Determination Clarification Act of 2017
-
ACMG Board Statement Regarding 2018 ACMG Annual Meeting to Be Held in Charlotte, NC and Discriminatory Legislation
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG Efforts Lead AMA Resolution 122 to Support Coverage of Medical Food Products
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG Response to FDA’s Proposed Regulatory Framework for LDTs
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs